Early Detection of Parkinson’s Focuses on Loss of Smell

NEW YORK (AP) — The Michael J. Fox Foundation for Parkinson’s‍ Research (MJFF) is emphasizing the importance of anosmia, or⁣ loss of smell, ⁢as⁢ a potential early warning sign of Parkinson’s disease. Researchers‍ at a recent meeting in New York ⁣discussed utilizing this symptom to improve early ⁤detection and intervention strategies.

Parkinson’s⁣ Progression ‍Markers Initiative

The MJFF highlighted it’s Parkinson’s Progression Markers Initiative (PPMI), a study launched in 2010, which is investigating biomarkers that could indicate the presence of Parkinson’s disease ⁤in its earliest stages.

Dr. Eduardo⁤ Tolosa, lead researcher at the University of Barcelona and a‍ leader within the PPMI, stated ‍that olfactory‍ dysfunction is evident in ‍90% of ⁢Parkinson’s ⁢patients, often appearing before more severe motor symptoms manifest.

In 2023, PPMI researchers identified specific markers, described as “biological and clinical footprints,” that can be detected even in individuals not yet diagnosed with the disease.

Tolosa said these markers, found in blood and skin samples, are enabling the foundation to propose a revised definition of Parkinson’s and improve disease monitoring.

Challenges in Parkinson’s Treatment

“The ‍Parkinson’s ‍cure has failed. There is no treatment that⁢ slows or prevents the disease,” Tolosa said, emphasizing the project’s shift toward prevention through clinical trials involving new medications for individuals exhibiting minor symptoms.

Tolosa noted that clinical trials over the past 20 years, conducted on patients ⁣with advanced Parkinson’s, have not yielded prosperous disease-modifying treatments.

Lowering the Age Threshold for Risk Assessment

The MJFF is advocating for lowering the minimum age for ‍genetic⁤ and risk assessments from 60 to⁢ 40. The goal is to identify individuals ⁤over 40 who test positive for genetic biomarkers, enabling the design of targeted⁤ prevention trials and a better understanding of ⁣the disease’s initial development.

Alicia Garrido, a neurologist at the Clinical Hospital of Barcelona and deputy ‍director of the PPMI, explained that‍ the ⁣previous age cutoff of 60 was⁣ based on the higher frequency of motor symptoms at that age. The shift reflects a move toward a “pre-engineer paradigm,” focusing on earlier intervention.

Disparities in Research Participation

U.S. studies indicate that the Hispanic or Latino community with Parkinson’s may experience more severe non-motor⁢ symptoms.However,⁤ only 7.6% of this population participates in research studies.

Online Platform for Data Contribution

The initiative’s ⁤digital platform, ‘MyPPMI,’ allows individuals over 18 in the U.S., ⁢Austria, England, Canada, Germany, Spain, and the Netherlands⁣ to contribute health and ‍wellness data. Expansion to additional countries ⁤is planned for later this year.

Barcelona was among the⁤ first⁤ European centers to join ⁤the PPMI project.A new phase involving smell tests for the ⁣general population is scheduled to begin next week,with the aim of expanding⁢ across⁣ Spain.

The MJFF reports that more than 46,000 participants have made approximately 222,000 visits to the online study, contributing data through over 3.3 million surveys.

Early Detection of Parkinson’s disease: Q&A

What ⁣is the main focus of early Parkinson’s research?

The Michael J.Fox Foundation for Parkinson’s Research (MJFF) is emphasizing the importance of anosmia, or loss of smell, as a potential ⁣early warning sign of Parkinson’s disease. Researchers are exploring how this symptom can⁣ improve early detection and ⁤intervention strategies.

What is the Parkinson’s Progression markers Initiative (PPMI)?

The⁢ PPMI is a study launched in 2010 by⁤ the MJFF. It investigates biomarkers, which are measurable ⁣indicators, that could suggest the presence of‍ Parkinson’s⁤ disease in its earliest stages.

why is loss ⁢of smell linked to Parkinson’s?

Dr.Eduardo Tolosa, a lead researcher with ⁢the PPMI, stated that olfactory dysfunction (loss⁢ of smell) is evident in 90% of⁤ Parkinson’s patients.This symptom often appears before more obvious motor symptoms, making it a valuable ⁣early indicator.

Have researchers identified specific markers for Parkinson’s?

Yes,in ⁢2023,PPMI researchers identified specific markers,described as “biological and clinical footprints,” that can be detected even⁤ in individuals not yet diagnosed with ⁢the disease. These markers are⁤ found in blood and skin samples.

How are these markers improving Parkinson’s research?

These markers are enabling ⁣the foundation to propose a revised definition of Parkinson’s and improve disease monitoring. This shift could ⁤help in early diagnosis and the potential for earlier interventions.

Is there a cure for Parkinson’s disease?

According to dr. tolosa, there is currently no treatment that slows or prevents ⁢the progression of the disease.However, the focus is shifting towards prevention through clinical trials.

What ⁢are the challenges in ‍treating Parkinson’s?

Clinical trials over the past 20 years, conducted on patients⁢ with advanced Parkinson’s, have not yielded successful disease-modifying treatments. This highlights the critical need for earlier detection and preventative strategies.

What is the MJFF⁤ doing to improve early detection?

The MJFF is advocating ⁤for lowering the minimum age for genetic and risk assessments from‍ 60 to 40.⁢ The purpose is to identify individuals over 40 who test positive⁤ for genetic biomarkers, enabling the ⁢design ⁣of targeted‍ prevention trials.

Why is the age threshold being lowered for assessments?

Previously,⁣ the age cutoff of 60 was based on the higher frequency of motor symptoms typically observed at that age. Shifting the focus to earlier intervention is a move towards a “pre-engineer paradigm,” to try to‍ alter the course of this disease ⁣before meaningful symptoms appear.

Dose participation in Parkinson’s research vary across different communities?

Yes. U.S. studies indicate that the Hispanic or Latino community with Parkinson’s ‍may experience ⁤more severe non-motor symptoms. ⁢However, onyl 7.6% of this population participates in research studies.

How can⁣ people contribute to Parkinson’s research?

the initiative has a digital platform called ‘MyPPMI,’ which allows individuals to contribute health and wellness data.

Who ⁤can participate in ‘MyPPMI’?

Individuals over 18 in the U.S., Austria, England, Canada, Germany, ‍Spain, and the‍ Netherlands are currently ⁢eligible‍ to contribute data⁣ through the online platform. ‍Expansion to other countries is‍ planned for later this year.

What data is collected through ‘MyPPMI’?

Participants contribute health and wellness data through surveys. Over 46,000 participants have made approximately 222,000 visits⁣ to the online study, contributing⁤ data through over 3.3 million surveys, according to the MJFF.

Where does the research take place?

Barcelona was one of the first European centers to join the PPMI project.‍ A new ⁣phase involving smell tests for the general population is scheduled to begin ⁣across Spain.

Key facts Summary

Here’s a recap of key information from the article:

Area of Focus	Details
Key symptom	Loss of smell (anosmia)
Initiative	Parkinson’s Progression Markers Initiative (PPMI)
Biomarkers	Identified⁢ in blood and skin samples
Age Threshold Change	lowering the minimum⁣ age for assessments from 60 to 40
Data Platform	MyPPMI (online platform for data contribution)